Digestive Diseases and Sciences

, Volume 48, Issue 1, pp 140–145 | Cite as

Intensive Interferon Therapy Does Not Increase Virological Response Rates in African Americans with Chronic Hepatitis C

  • Dickens Theodore
  • Mitchell L. Shiffman
  • Richard K. Sterling
  • Christine J. Bruno
  • Jeffrey Weinstein
  • Jeffrey S. Crippin
  • Gabriel Garcia
  • Teresa L. Wright
  • Hari Conjeevaram
  • Rajender K. Reddy
  • Frederick S. Nolte
  • Michael W. Fried

Abstract

To determine if an intensive regimen of daily, high-dose interferon would improve the initial response rates to therapy for hepatitis C genotype 1 among African American and Caucasian patients, we conducted a retrospective analysis of a treatment trial conducted between October 1995 and June 1997. Patients were randomized to 24 weeks of therapy with interferon −α-2b at either 5 MU daily or 3 MU three times a week. On the standard interferon regimen (3 MU three times a week) African Americans and Caucasians had similar initial response rates. However, unlike Caucasians, African Americans did not have an increased initial virological response when treated with an intensive, daily dose regimen. Levels of HCV RNA decreased more slowly during the first 12 weeks of therapy among African Americans. Nelson-Aalen cumulative hazard estimates for the different race and dose combinations revealed that Caucasians who received daily interferon were most likely to have an initial response (logrank, P < 0.001).

hepatitis C interferon therapy race African American 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

REFERENCES

  1. 1.
    Reddy KR, Hoofnagle JH, Tong MJ, Lee WM, Pockros P, Heathcote EJ, Albert D, Joh T: Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group. Hepatology 30:787-793, 1999Google Scholar
  2. 2.
    McHutchison JG, Poynard T, Pianko S, Gordon SC, Reid AE, Dienstag J, Morgan T, Yao R, Albrecht J: The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. Gastroenterology 119:1317-1323, 2000Google Scholar
  3. 3.
    Howell C, Jeffers L, Hoofnagle JH: Hepatitis C in African Americans: Summary of a workshop. Gastroenterology 119:1385-1396, 2000Google Scholar
  4. 4.
    Kimball P, Elswick RK, Shiffman M: Ethnicity and cytokine production gauge response of patients with hepatitis C to interferon-alpha therapy. J Med Virol 65:510-516, 2001Google Scholar
  5. 5.
    Fried MW, Shiffman ML, Sterling RK, Weinstein J, Crippin J, Garcia G, Wright TL, Conjeevaram HS, Reddy KR, Peter J, Cotsonis GA, Nolte FS: Amulticenter, randomized trial of daily high-dose interferon-alfa 2b for the treatment of chronic hepatitis C: pretreatment stratification by viral burden and genotype. AmJ Gastroenterol 95:3225-3229, 2000Google Scholar
  6. 6.
    Fried MW: Advances in therapy for chronic hepatitis C. Clin Liver Dis 5:1009-1023, 2001Google Scholar
  7. 7.
    ShiffmanML:Use of high-dose interferon in the treatment of chronic hepatitis C. Semin Liver Dis 19 (suppl 1):25-33, 1999Google Scholar
  8. 8.
    Layden TJ, Lam NP, Wiley TE: Hepatitis C viral dynamics. Clin Liver Dis 3:793-810, 1999Google Scholar
  9. 9.
    Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, Perelson AS: Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 282:103-107, 1998Google Scholar
  10. 10.
    Lam NP, NeumannAU, Gretch DR, Wiley TE, Perelson AS, Layden TJ: Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology 26:226-231, 1997Google Scholar
  11. 11.
    Bekkering FC, Brouwer JT, Leroux-Roels G, Van Vlierberghe H, Elewaut A, Schalm SW: Ultrarapid hepatitis C virus clearance by daily high-dose interferon in nonresponders to standard therapy. J Hepatol 28:960-964, 1998Google Scholar
  12. 12.
    Kinzie JL, Naylor PH, Nathani MG, Peleman RR, Ehrinpreis MN, Lybik M, Turner JR, Janisse JJ, Massanari M, Mutchnick MG: African Americans with genotype 1 treated with interferon for chronic hepatitis C have a lower end of treatment response than Caucasians. J Viral Hepat 8:264-269, 2001Google Scholar
  13. 13.
    Wiley TE, Mika BP, McCarthy ME, Layden TJ: Pre-treatment differences between HCV-infected African American and non-African American patients. Hepatology 30:265A, 1999Google Scholar
  14. 14.
    Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, Kaslow RA, Margolis HS: The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 341:556-562, 1999Google Scholar
  15. 15.
    Kaufman JS, Cooper RS: Commentary: considerations for use of racial/ethnic classification in etiologic research. Am J Epidemiol 154:291-298, 2001Google Scholar
  16. 16.
    Cooper RS, Freeman VL: Limitations in the use of race in the study of disease causation. J Natl Med Assoc 91:379-383, 1999Google Scholar
  17. 17.
    Witzig R: The medicalization of race: scientific legitimization of a flawed social construct. Ann Intern Med 125:675-679, 1996Google Scholar
  18. 18.
    Senior PA, Bhopal R: Ethnicity as a variable in epidemiological research. BMJ 309:327-330, 1994Google Scholar
  19. 19.
    Lindsay KL, McHutchison JG, Ling M-H, Albrecht JK: Response to PEG-IFN a2b (PEG-Intron) in blacks and hispanics with HCV is higher than with standard IFN a2b (IFN). Hepatology 32:347A, 2000Google Scholar
  20. 20.
    Shiffman ML, Fromm H, Mills P, Moonka Dk, Fried MW, Berg C, Sherman M, Coleman S, Marsano LS, Reddy KR, Brunda MJ, De Pamphilis J: Enhanced efficacy of pegylated (40kda) interferon alfa-2a (Pegasys) compared with interferon alfa-2a (Roferon-A) for chronic hepatitis C in blacks. Hepatology 32:348A, 2000Google Scholar

Copyright information

© Plenum Publishing Corporation 2003

Authors and Affiliations

  • Dickens Theodore
    • 1
  • Mitchell L. Shiffman
    • 2
  • Richard K. Sterling
    • 2
  • Christine J. Bruno
    • 3
  • Jeffrey Weinstein
    • 4
  • Jeffrey S. Crippin
    • 4
  • Gabriel Garcia
    • 5
  • Teresa L. Wright
    • 6
  • Hari Conjeevaram
    • 7
  • Rajender K. Reddy
    • 8
  • Frederick S. Nolte
    • 3
  • Michael W. Fried
    • 1
  1. 1.University of North Carolina at Chapel HillNorth Carolina
  2. 2.Medical College of VirginiaVirginia
  3. 3.Emory UniversityAtlantaGeorgia
  4. 4.Baylor UniversityDallasTexas
  5. 5.Stanford UniversityPalo AltoCalifornia
  6. 6.University of CaliforniaSan FranciscoCalifornia
  7. 7.University of MichiganMichigan
  8. 8.University of MiamiFloridaUSA

Personalised recommendations